Meeting Prep: Prof. Christopher

Meeting Context

Calendar entry shows external meeting with "Prof. Christopher" - extended 2.5-hour block suggests in-depth discussion or site visit.

Possible Attendee Profile

Research identified several Professor Christopher cardiologists, though none with primary ATTR-CM specialization:

Potential Matches

1. Christopher V. DeSimone, M.D., Ph.D. (Mayo Clinic)

- Not primarily amyloidosis-focused

1. Christopher M. Kramer (University of Virginia)

- Relevant for ATTR-CM diagnosis/monitoring via imaging

1. Christopher Nguyen, Ph.D. (Cleveland Clinic)

- Technical imaging expertise applicable to ATTR-CM

1. Christopher L. Hansen, M.D. (Thomas Jefferson University)

- Imaging/diagnostics focus

Current ATTR-CM Diagnostic Landscape

• No simple efficacy test for tafamidis - efficacy monitored indirectly through:

- Echocardiography measurements

- Cardiac MRI (key for diagnosis and progression tracking)

- Functional tests and symptom assessments

• Early diagnosis critical: Tafamidis protective effect more pronounced in younger patients and earlier-stage disease

Strategic Context for Ada

If this is an imaging/diagnostics expert, potential collaboration areas:

1. Patient identification: Leveraging cardiac imaging data to identify undiagnosed ATTR-CM
2. Monitoring protocols: Standardized imaging-based progression tracking
3. Academic partnership: Clinical research on real-world outcomes
4. Advisory role: Scientific validation of Ada's patient finder methodology

Key ATTR-CM Market Updates (Feb 2026)

• Tafamidis initiated in 80% of new cases (multicenter analysis, Feb 9, 2026)
• Survival improvement: patients diagnosed 2018-2021 lived >5 years average
• Treatment reduces all-cause death risk by ~29%
• Competition: acoramidis (Attruby) and vutrisiran (Amvuttra) gaining traction
• Pricing pressure: cost-effectiveness concerns above $13,600-$39,000 annually

Strategic Talking Points

1. Diagnostic gap: Many ATTR-CM patients remain undiagnosed; imaging protocols can improve identification
2. Monitoring challenge: No direct tafamidis efficacy measure; imaging plays critical role in tracking response
3. Early intervention: Tafamidis most effective in early-stage disease - imaging-based early detection is crucial
4. Real-world evidence: Academic partnerships can validate patient identification and treatment response monitoring approaches

Questions to Ask

1. What's your current research focus in cardiac imaging/ATTR-CM?
2. What challenges do you see in ATTR-CM diagnosis and monitoring in clinical practice?
3. What role do you see for technology-enabled patient identification?
4. Would you be interested in exploring a research collaboration around [specific area based on expertise]?
5. What metrics matter most to you when evaluating disease progression?

Materials to Prepare

• Ada pitch deck (if appropriate)
• Patient finder demo or case study
• Published research on ATTR-CM diagnostic delays
• ROI illustration showing value of early identification

Commitments to Avoid

• No specific patient identification claims without validation
• No forward-looking statements about Ada's technology capabilities
• No discussion of proprietary algorithms without NDA

Follow-up Actions

• Send thank-you with summary of discussion points
• Provide requested materials (research papers, case studies, demo access)
• Propose next steps if collaboration interest exists
• Introduce to relevant Ada team members if appropriate